At a Glance
- U.S. Section 232 treatment distinguishes patented pharmaceutical articles from generic pharmaceutical articles.
- Generic pharmaceutical articles and associated ingredients currently have a 0% Section 232 rate.
- Covered patented products can face a 100% rate, subject to lower rates or exemptions based on origin and eligibility.
- Product classification, country of origin, patent status, and company agreements affect the applicable duty.
- Buyers should validate tariff treatment before accepting a supplier quote or calculating landed cost.
What You’ll Learn
This guide explains how current U.S. pharmaceutical tariff treatment works and what import buyers should verify before sourcing or costing a shipment.
Introduction
The pharmaceutical tariffs list is not a simple list of prescription-drug names. It is an import-classification question that depends on the imported article, its country of origin, its patent or generic status, and any qualifying agreement or exclusion.
For procurement teams, the immediate task is to identify the imported article, confirm its HTSUS treatment, and establish whether a lower rate or exclusion applies. Buyers should not use older tariff announcements as the basis for current landed-cost decisions.
Current U.S. Pharmaceutical Tariff Status
The April 2026 Section 232 action established tariff treatment for covered patented pharmaceutical articles and associated pharmaceutical ingredients. The applicable rate depends on current HTSUS provisions and CBP instructions, so buyers should confirm treatment for each product before quoting or importing.
|
Import category |
Current Section 232 treatment |
Buyer check before quoting |
|
Covered patented pharmaceutical articles and associated ingredients |
100% rate unless a lower rate applies |
Confirm HTSUS coverage, origin, patent status, and entry date |
|
Products of the EU, Japan, South Korea, Switzerland, or Liechtenstein |
15% rate unless a lower rate applies |
Confirm origin and alternate eligibility |
|
Products under an approved qualifying onshoring plan |
20% rate, scheduled to increase to 100% on April 2, 2030 |
Confirm approval and ongoing eligibility |
|
Products with qualifying onshoring and MFN pricing agreements |
0% rate through January 20, 2029 |
Confirm agreement status and product scope |
|
Generic pharmaceutical articles and associated ingredients |
0% Section 232 rate at present |
Confirm generic classification and current CBP instructions |
|
Certain specialty, clinical-trial, research, and non-commercial products |
0% where applicable conditions are met |
Confirm eligibility and supporting documentation |
What drugs will be affected by tariffs?
Covered patented pharmaceutical articles and associated ingredients may be affected. Generic pharmaceutical articles are currently excluded from Section 232 tariffs, but treatment should be reviewed at the SKU and shipment level.
A pharmaceutical tariffs list of drugs should be treated as a compliance output, not a static editorial list. The final determination depends on product classification, origin, patent status, entry date, and documented eligibility.
Read the April 2026 proclamation and current CBP guidance before making a commercial decision.
Where Do Our Drugs Actually Come From?
U.S. imports of pharmaceuticals totaled about $213 billion in 2024, a threefold increase from a decade earlier. The supply chain is genuinely global.
Major Sources:
- Ireland: 24% of U.S. pharmaceutical imports (largely branded drugs)
- European Union overall: 61% of total imports
- Switzerland: 9% of imports
- Singapore: 8% of imports
- India: 6% of imports (mostly generics and APIs)
- China: 3% of imports (surprisingly small given the rhetoric)
Ireland’s imports in March 2025 were five times higher than the same month a year ago as companies stockpiled inventory ahead of potential tariffs. That’s not sustainable. You can’t build years of inventory for every medication.
For generics, the picture looks different. The U.S. relies on producers in India and China for generic drugs, where about 35% of the world’s active pharmaceutical ingredients for generics are produced in India. These lower-cost manufacturing locations make affordable generic medications possible.
The Pfizer Deal: Blueprint for Others
September 30, 2025 marked a turning point. Pfizer announced a historic agreement with the Trump Administration to ensure U.S. patients pay lower prices for their prescription medicines while strengthening America’s role in biopharmaceutical innovation.
What did Pfizer agree to?
Pricing Commitments:
- Most-Favored-Nation pricing to all state Medicaid programs
- Launch new drugs in the U.S. at the same prices offered to other developed countries
- Direct-to-consumer sales at average 50% discounts through TrumpRx.gov website
- Specific medications discounted 40-85% for cash-paying patients
Manufacturing Investment: Pfizer committed $70 billion to U.S. research, development and capital projects over the next several years. That’s not pocket change. That’s building facilities, hiring workers, and moving production stateside.
What Pfizer Got:
- Three-year exemption from pharmaceutical tariffs
- Certainty for long-term planning
- Competitive advantage over companies that haven’t signed deals
Examples of discounted drugs include Eucrisa at an 80% discount, Xeljanz at a 40% discount, and Zavzpret at a 50% discount for patients purchasing directly. For someone paying cash, that’s substantial savings. But there’s a catch.
These discounts only apply to patients not using insurance. The website deals would only be accessible for patients not using their health insurance, and even then, the discounted medicines might not be affordable because they’re based on high drug list prices. If your insurance negotiates better rates through pharmacy benefit managers, you might actually pay less at the pharmacy counter with your regular coverage.
Who Gets Hit Hardest by Tariffs on Pharmaceuticals?
Not every company faces the same pressure from these tariffs. Size, manufacturing footprint, and profit margins determine vulnerability.
Companies Best Positioned:
- Eli Lilly (significant U.S. manufacturing presence)
- Johnson & Johnson (announced $55 billion U.S. investment)
- AbbVie (majority production in U.S.)
- Bristol Myers Squibb (extensive domestic facilities)
Companies More Exposed:
- Novo Nordisk (limited U.S. manufacturing, though expanding)
- Roche (few U.S. facilities relative to global operations)
- Smaller biotech companies without resources for new plants
- Generic manufacturers with thin profit margins
According to industry experts, the new tariffs will likely have the most impact on small and mid-sized manufacturers of brand-name medications who typically manufacture medications in Canada, Mexico, or the Middle East and cannot afford to spend billions on building new facilities in the United States.
Think about what this means practically. A major pharmaceutical company like Pfizer or Eli Lilly can write a $50-70 billion check for U.S. manufacturing expansion. They’ve got the capital, the infrastructure knowledge, and the scale to make it work. A mid-sized biotech company developing specialized treatments for rare diseases? They’re operating on venture capital funding and every dollar counts. Building a new manufacturing facility isn’t feasible.
Those smaller companies face impossible choices:
- Pay the 100% tariff and watch profits evaporate
- Raise prices and potentially lose market access
- Exit the U.S. market entirely
- Get acquired by a larger company with U.S. facilities
None of those options benefit patients.
Generic Drug Manufacturers Face Different Math
Generic drug manufacturers, who are already squeezed with lower profit margins, could be forced to leave the U.S. market altogether if tariffs extend to generics. Generic medications sell at close to manufacturing cost. There’s no cushion to absorb a 100% tariff.
Right now, generics are explicitly exempt. But what if that changes? Offshore generic manufacturers faced with tariffs may abandon the production of drugs with already small financial margins. We’re not talking about minor inconveniences. We’re talking about antibiotics, blood pressure medications, diabetes treatments, and other essential drugs.
In the first three months of 2024, a record 323 drugs were in shortage, and 70% of drug shortages are related to generics. Tariffs on generics would turn a serious problem into a crisis.
Will Drug Prices Actually Go Up?
The billion-dollar question. Literally.
For branded drugs, the answer depends on several factors:
Factors That Could Increase Prices:
- Companies passing tariff costs to insurers and patients
- Supply chain disruptions causing shortages
- Reduced competition as smaller manufacturers exit
- Higher manufacturing costs in the U.S. versus abroad
Factors That Might Limit Increases:
- Most major drugmakers securing exemptions through manufacturing commitments
- Competition between similar branded drugs
- Medicare/Medicaid price controls limiting passthrough
- Public and political pressure to keep prices stable
A Budget Lab at Yale University projection indicated that a 25% ad valorem tariff would increase medication costs by an average of around $600 per year per household in the United States. That was for a 25% tariff. We’re talking about 100% for non-exempt drugs.
But here’s the counterargument. Eli Lilly CEO David Ricks stated that drug companies like his would be forced to take on the full burden of tariffs rather than pass costs to consumers because there are so many controls on the price of medicines. Companies with monopoly positions on specific molecules can’t easily raise prices without triggering regulatory scrutiny and losing formulary access.
| Drug Category | Likely Price Impact | Reasoning |
| Generic medications | Minimal to none | Exempt from tariffs |
| Branded drugs (major companies) | Low to moderate | Companies securing exemptions |
| Specialty medications (small companies) | Moderate to high | Less ability to absorb costs or secure exemptions |
| Drugs with competition | Low | Market forces limit price increases |
| Monopoly drugs | Moderate | Limited by regulatory controls but some passthrough likely |
For most Americans with insurance, drug prices depend on factors including competition a treatment faces and insurance coverage, with most people having coverage through work, individual market, or government programs that shields them from much of the cost. Your copay might stay the same even if the underlying drug cost increases because your insurance company negotiates rates and sets fixed copays.
But for the uninsured or those with high-deductible plans? Different story. Cash prices could climb significantly for non-exempt medications.
Manufacturing Reshoring: Promise vs. Reality
Trump’s stated goal is bringing pharmaceutical manufacturing back to America. Is it working?
Recent U.S. Manufacturing Commitments:
- Pfizer: $70 billion
- Johnson & Johnson: $55 billion
- AstraZeneca: $50 billion
- Sanofi: $20 billion
- Eli Lilly: $6.5 billion Texas facility for obesity drugs
- Novo Nordisk: North Carolina plant (operational 2029)
That’s over $200 billion in announced investments. Impressive numbers. But let’s dig deeper.
The labs needed to produce complex branded drugs, like injection drugs and more complicated oral medicines, take years to set up, with Novo Nordisk’s North Carolina plant announced in 2024 not operational until 2029. Manufacturing facilities don’t materialize overnight. We’re talking 3-7 year timelines for major pharmaceutical plants.
The complexity matters too. Manufacturing processes for finished dosage forms can be specialized to type of formulation and type of drug, with sterile injectables made with very different machinery than oral dose products. Building a facility to make tablets doesn’t help if you need to manufacture biologic injections.
The Generic Manufacturing Problem
Reshoring generic manufacturing will never lead to lower consumer costs, as the costs of importing ingredients and materials and paying higher U.S. labor costs to manufacture generic products in the United States will exceed those in China and India.
That’s the hard truth. Generic drugs stay cheap because they’re manufactured in countries with lower labor costs and established supply chains for raw materials. Moving that production to the U.S. means higher wages, stricter environmental regulations, and more expensive facilities. All of that gets baked into the drug price.
Americans want affordable medications AND U.S. manufacturing jobs. You can’t always have both. At least not without massive government subsidies that taxpayers ultimately fund through other mechanisms.
Supply Chain Disruptions and Drug Shortages
Here’s something that doesn’t get enough attention. Supply chains are globally interconnected, and China, India, Ireland, and a few other European countries supply a large fraction of generic and branded medications to the United States as either finished products or intermediate ingredients.
Tariffs don’t just affect finished drugs. They affect:
- Active pharmaceutical ingredients (APIs)
- Excipients and inactive ingredients
- Packaging materials
- Intermediate chemical compounds
- Laboratory equipment and supplies
The Trump Administration’s pharmaceutical tariffs would impact finished products and intermediate goods including ingredients and packaging materials for domestic manufacturing. Even U.S.-based manufacturers rely on imported components.
Supply Chain Vulnerability Points:
- Single-source APIs from specific countries
- Specialized manufacturing equipment with long lead times
- Quality control delays at customs
- Stockpiling creating artificial shortages
- Just-in-time inventory systems breaking down
News of possible tariffs led to increased inbound shipments and domestic stockpiling by drug companies, with impending shortages triggering panic buying by hospitals and pharmacies. That’s already happening. Hospitals are hoarding inventory. Manufacturers are shipping as much as possible before tariffs hit. The result? Shortages elsewhere in the supply chain.
Innovation and R&D: The Long-Term Cost
Something nobody’s talking about much: research and development funding.
The pharmaceutical industry relies heavily on profits and capital markets to fund research and development, with tariffs creating uncertainty in currency, stock, and bond markets that negatively impacts access to capital supporting industry investments in innovations.
Every dollar spent paying tariffs is a dollar not spent on:
- Clinical trials for new medications
- Basic research into disease mechanisms
- Drug candidate screening and development
- Regulatory approval processes
- Post-market safety studies
Smaller pharmaceutical companies and startups, which play a critical role in innovation and drug discovery, are particularly vulnerable to capital market fluctuations and increased operational costs from tariffs. These are the companies developing breakthrough treatments for rare diseases, novel cancer therapies, and next-generation antibiotics. They operate on thin margins and investor funding. Tariffs eat into already limited resources.
Market consolidation becomes inevitable. Big companies acquire smaller ones to gain their drug portfolios and eliminate tariff exposure. By disproportionately harming smaller firms, tariffs could ultimately lead to market consolidation and decreased consumer choice.
Less competition means higher prices long-term, even if tariffs achieve short-term manufacturing goals.
Navigating the New Reality
So where does this leave everyone?
For Patients:
- Generic medications should remain largely unaffected
- Branded drug prices may increase for some specialty medications
- Direct-to-consumer purchasing options expanding through TrumpRx.gov and company websites
- Insurance coverage and copays remain critical for affordability
- Some medications might face temporary shortages as supply chains adjust
For Healthcare Providers:
- More complex formulary management as drug availability shifts
- Potential need for therapeutic substitutions if specific products become unavailable
- Price transparency becoming more important for cash-pay patients
- Prior authorization processes possibly changing as insurers respond to price shifts
For Pharmaceutical Companies:
- Massive capital requirements for U.S. manufacturing expansion
- Strategic decisions about which products to manufacture domestically
- Ongoing negotiations with administration on pricing and investment commitments
- Supply chain restructuring and diversification
- Increased focus on direct-to-consumer sales channels
Procurement Actions for Pharmaceutical Buyers
Before issuing an RFQ or changing a landed-cost model, document the product name, CAS number where applicable, dosage form or material role, HTSUS classification, country of origin, patent or generic status, supplier entity, and expected entry date.
Ask the importer of record or qualified customs counsel to confirm whether Section 232 treatment, a lower country-specific rate, or an exclusion applies. For general classification context, see Elchemy’s U.S. tariff codes guide.
Bottom Line
Pharmaceutical tariff exposure is now a classification and documentation issue, not a single industry-wide percentage. Generic articles, covered patented products, associated ingredients, origin-specific treatment, and company agreements can lead to different outcomes for similar shipments.
Before approving a supplier, shipment date, or landed-cost estimate, verify the product classification, origin, patent or generic status, expected entry date, and current CBP guidance.
Need to evaluate pharmaceutical-import sourcing options? Request a Quote with the product name, dosage form or material role, country of origin, required quantity, destination, expected entry date, and required documentation.
